Arcus Biosciences annual meeting results and revised director comp: $45k retainer, $750k initial equity

Arcus Biosciences, Inc.

All four director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved with ~92% for.
Board revised non-employee director compensation: annual cash retainer $45,000; additional committee chair retainers up to $25,000.
Initial equity award ~$750,000 (2/3 options, 1/3 RSUs) with 3-year vesting; annual award ~$400,000 with 12-month or next meeting vesting.
Compensation changes effective June 15, 2023, as detailed in Exhibit 10.1.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-15 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 56,058,305 2,350,776 50,777 8,655,281

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved Election of directors at the 2023-06-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

Proposal 1 : The election of a director to hold office until the 2026 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dr. David Lacey 40,854,980 17,604,878 8,655,281 Dr. Juan Jaen 43,694,709 14,765,149 8,655,281 Dr. Merdad Parsey 42,680,149 15,779,709 8,655,281 Ms. Nicole Lambert 46,262,513 12,197,345 8,655,281

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcus Biosciences, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

Proposal 2 : The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 65,921,166 1,127,268 66,708

View on SEC.gov

Browse all shareholder votes →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-028621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.